{"id":11481,"date":"2026-11-09T18:19:06","date_gmt":"2026-11-09T12:49:06","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/gland-share-price-today-2026-11-09\/"},"modified":"2026-11-09T18:19:08","modified_gmt":"2026-11-09T12:49:08","slug":"gland-share-price-today-2026-11-09","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/gland-share-price-today-2026-11-09\/","title":{"rendered":"Gland Pharma Share Price Today: Why GLAND Is Rising 5.41% | 9 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: GLAND<\/strong> \u00b7 9 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b93,302.40<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+5.41%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b93,374.00 \/ \u20b93,140.80<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b93,132.80<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>24.37 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>9 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Gland Pharma Ltd. shares rose 5.41% today, finishing at \u20b93,302.40 after moving within a wide intraday range of \u20b93,140.80 and \u20b93,374.00.<\/li>\n<li>Gland Pharma announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 09, 2026. Mr. Xiao Le brings over 15 years of experience in investment and asset management across medical devices, biopharma, and healthcare services, holding degrees from Johns Hopkins University and MIT. He will be responsible for exploring investment opportunities and improving M&amp;A capabilities in the U.S., China, Singapore, and other regions.<\/li>\n<li>Trading volume was 6.86 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Gland Pharma share price rising on 9 November 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Gland Pharma Ltd. shares rose 5.41% today, finishing at \u20b93,302.40 after moving within a wide intraday range of \u20b93,140.80 and \u20b93,374.00.<\/p>\n<p class=\"wt-copy\">The broader pharmaceutical sector experienced positive momentum today, with the Nifty Pharma sector benchmark advancing 3.42%, while the broader Nifty inched up by 0.06%. Gland Pharma outperformed both the broader market and its sector benchmark, building upon a 5-day return of 7.69% and a 20-day return of 7.86%.<\/p>\n<p class=\"wt-copy\">Company disclosures from recent days include the appointment of Mr. Xiao Le as Chief Investment Officer for Gland Pharma International Pte. Ltd., effective November 09, 2026, to oversee M&amp;A and investment opportunities across the U.S., China, and Singapore. While this operational update provides context on ongoing management strengthening, its direct link to today&#x27;s intraday price action remains part of broader corporate developments.<\/p>\n<p class=\"wt-copy\">24.37 lakh shares traded by 9 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 3.55 lakh shares (6.86 times). The five-day average daily volume was 4.04 lakh shares. Separately, the NSE report for 9 November 2026 showed 5.60 lakh shares delivered, representing 22.98% of that day\u2019s traded volume. The same report recorded 216,218 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Strong sector tailwinds and high volume participation<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s 5.41% gain aligns with strong outperformance within the Nifty Pharma sector, backed by heavy cash volume exceeding 6.86 times the 20-day average and ongoing positive sentiment following recent quarterly results and management expansions.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Appointment of Chief Investment Officer for Singapore Subsidiary<\/div>\n<div class=\"wt-card-date\">9 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Gland Pharma announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 09, 2026. Mr. Xiao Le brings over 15 years of experience in investment and asset management across medical devices, biopharma, and healthcare services, holding degrees from Johns Hopkins University and MIT. He will be responsible for exploring investment opportunities and improving M&amp;A capabilities in the U.S., China, Singapore, and other regions.<\/p>\n<p class=\"wt-copy\">Strengthens leadership for international expansion and strategic M&amp;A initiatives in core overseas markets.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLAND_09112026095359_Appointment_of_CIO.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Postal Ballot Voting Results for Director Appointment<\/div>\n<div class=\"wt-card-date\">7 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company submitted the scrutinizer&#x27;s report and voting results for its postal ballot that concluded on November 05, 2026. Shareholders approved the ordinary resolution for the appointment of Mr. Xingli Wang as a Non-Executive and Non-Independent Director with the requisite majority of 97.06% of total votes polled.<\/p>\n<p class=\"wt-copy\">Formalizes board composition updates following remote e-voting participation by institutional and non-institutional members.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLAND_06112026222930_PBvotingresults_05112026_Final.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2 FY27 Financial Results and Business Updates<\/div>\n<div class=\"wt-card-date\">6 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Gland Pharma reported its financial performance for the quarter ended September 30, 2026, posting a 23% year-on-year increase in revenue from operations to \u20b918,336 million and a 58% growth in profit after tax to \u20b92,908 million. The CDMO business grew 31% year-on-year to \u20b98,227 million, while Critical Injectables expanded by 18% to \u20b910,109 million.<\/p>\n<p class=\"wt-copy\">Demonstrates robust operational execution and double-digit growth across key business verticals.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Appointment<\/div>\n<div class=\"wt-card-date\">9 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Appointment of Mr Xiao Le as the Chief Investment Officer for Gland Pharma International Pte. Ltd (Wholly- owned subsidiary of Gland Pharma Limited), effective November 09, 2026<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLAND_09112026095359_Appointment_of_CIO.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Gland Pharma shares jump 4% as Q2 profit jumps 58%, revenue rises 23% YoY &#8211; The Economic Times<\/div>\n<div class=\"wt-card-date\">9 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Gland Pharma shares jump 4% as Q2 profit jumps 58%, revenue rises 23% YoY The Economic Times<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLAND_09112026095359_Appointment_of_CIO.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">45.75%<\/div>\n<div class=\"wt-note\">51.77% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">10.36%<\/div>\n<div class=\"wt-note\">8.74% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">43.57%<\/div>\n<div class=\"wt-note\">39.18% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739563_16102026115909_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>A. JAYATHEERTHA<\/strong><span class=\"wt-note\">Employees\/Designated Employees<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>100 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>9 February 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>A. JAYATHEERTHA<\/strong><span class=\"wt-note\">Employees\/Designated Employees<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>306 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>2 February 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>P LAKSHMI NARAYANA<\/strong><span class=\"wt-note\">Employees\/Designated Employees<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>800 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>2 February 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>P LAKSHMI NARAYANA<\/strong><span class=\"wt-note\">Employees\/Designated Employees<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>300 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>21 November 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 29.52% on 30 September 2026. This compares with 28.23% on 30 June 2026, a change of +1.29 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 31 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Mutual Fund &#8211; Hdfc Mid-Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">92.43 lakh shares \u00b7 5.60%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">80.41 lakh shares \u00b7 4.87%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Large &amp; Midcap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">52.73 lakh shares \u00b7 3.20%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739563_16102026115909_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Jefferies<\/div>\n<div class=\"wt-card-date\">11 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Upgraded the stock following strong quarterly financial performance and solid midcap positioning.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Bofa Securities Europe Sa<\/div>\n<div class=\"wt-card-date\">17 September 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 1.50 lakh shares \u00b7 \u20b92,826.60<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">North Rock Sg Vcc<\/div>\n<div class=\"wt-card-date\">17 September 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 1.50 lakh shares \u00b7 \u20b92,826.60<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Kotak Mahindra Mutual Fund<\/div>\n<div class=\"wt-card-date\">4 September 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 27.93 lakh shares \u00b7 \u20b92,826.60<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Fosun Pharma Industrial Pte. Ltd.<\/div>\n<div class=\"wt-card-date\">4 September 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 27.93 lakh shares \u00b7 \u20b92,826.60<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution of technology transfer activities under the global CDMO partnership<\/li>\n<li>Progress on U.S. regulatory filings and commercialization of the 24 filed Ready-to-Use infusion bags<\/li>\n<li>Integration and performance of newly acquired step-down subsidiary Novelstar Pharma Inc.<\/li>\n<li>Sustained delivery volumes and cash market participation relative to the 20-day average<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/gland\/\">More Gland Pharma news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Gland Pharma company news?<\/h3>\n<p class=\"wt-copy\">Gland Pharma announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 09, 2026. Mr. Xiao Le brings over 15 years of experience in investment and asset management across medical devices, biopharma, and healthcare services, holding degrees from Johns Hopkins University and MIT. He will be responsible for exploring investment opportunities and improving M&amp;A capabilities in the U.S., China, Singapore, and other regions.<\/p>\n<h3>How strong was Gland Pharma\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">24.37 lakh shares traded, 6.86 times the 20-day average daily volume. The price and volume data are dated 9 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/gland-share-price-today-2026-11-09\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/gland-share-price-today-2026-11-09\/\"}, \"headline\": \"Gland Pharma Share Price Today: Why GLAND Is Rising 5.41% | 9 November 2026\", \"description\": \"Gland Pharma share price rose 5.41% to \u20b93,302.40 today. See why GLAND is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-11-09T18:18:53.159086+05:30\", \"dateModified\": \"2026-11-09T18:18:53.159086+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Gland Pharma\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"GLAND\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/gland-company-news-2026-11-09.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Appointment\",\"summary\":\"Appointment of Mr Xiao Le as the Chief Investment Officer for Gland Pharma International Pte. Ltd (Wholly- owned subsidiary of Gland Pharma Limited), effective November 09, 2026\",\"source\":\"NSE\",\"published\":\"09-Nov-2026 09:54:23\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLAND_09112026095359_Appointment_of_CIO.pdf\"},{\"title\":\"Gland Pharma shares jump 4% as Q2 profit jumps 58%, revenue rises 23% YoY - The Economic Times\",\"summary\":\"Gland Pharma shares jump 4% as Q2 profit jumps 58%, revenue rises 23% YoY The Economic Times\",\"source\":\"The Economic Times\",\"published\":\"Mon, 09 Nov 2026 05:26:55 GMT\",\"source_type\":\"business media\",\"generic_watchlist\":false}],\"recent_news\":[{\"summary\":\"Gland Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.\",\"category\":\"Shareholders meeting\",\"date\":\"06-Nov-2026 22:29:39\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLAND_06112026222930_PBvotingresults_05112026_Final.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"a press release dated November 06, 2026, titled \\\"Press Release on Q2FY27 Financial Results \\\".\",\"category\":\"Press Release\",\"date\":\"06-Nov-2026 17:04:22\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLAND_06112026170413_PressReleaseQ2FY27_Final.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"06-Nov-2026 16:33:34\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLAND_06112026162953_OutcomeBMQ2FY27_Final.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Gland Pharma Q1 Results: Profit Spikes 47% As Margins Expand; Revenue Hits Rs 1,800 Crore.\",\"category\":\"Business media\",\"published\":\"2026-08-10T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4}],\"insider_activity\":[{\"person\":\"A. JAYATHEERTHA\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"100\",\"post_holding\":\"3928\",\"date\":\"09-Feb-2026\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"A. JAYATHEERTHA\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"306\",\"post_holding\":\"4028\",\"date\":\"02-Feb-2026\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"P LAKSHMI NARAYANA\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"800\",\"post_holding\":\"Nil\",\"date\":\"02-Feb-2026\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"P LAKSHMI NARAYANA\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"300\",\"post_holding\":\"800\",\"date\":\"21-Nov-2025\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":45.75,\"public_pct\":54.25,\"fii_pct\":10.36,\"dii_pct\":33.21,\"mf_pct\":29.52,\"institutional_pct\":43.57,\"noninst_pct\":10.66,\"mf_scheme_count\":31,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Hdfc Mutual Fund - Hdfc Mid-Cap Fund\",\"shares\":9242690,\"pct\":5.6},{\"name\":\"Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund\",\"shares\":8040644,\"pct\":4.87},{\"name\":\"Sbi Large &amp; Midcap Fund\",\"shares\":5273017,\"pct\":3.2},{\"name\":\"Mirae Asset Large &amp; Midcap Fund\",\"shares\":4811091,\"pct\":2.92},{\"name\":\"Axis Mutual Fund Trustee Limited A\/C Axis Mutual Fund A\/C Axis Small Cap Fund\",\"shares\":4138847,\"pct\":2.51}],\"period\":\"30-SEP-2026\",\"submission_date\":\"16-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739563_16102026115909_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":51.77,\"previous_fii_pct\":8.74,\"previous_dii_pct\":30.44,\"previous_mf_pct\":28.23,\"previous_institutional_pct\":39.18,\"previous_mf_scheme_count\":27,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Jefferies\",\"rating\":\"Buy\",\"target\":null,\"view_summary\":\"Gland Pharma stock jumps 12%, top midcap gainer after strong Q1; Jefferies upgrades to Buy, check target...\",\"headline\":\"Gland Pharma stock jumps 12%, top midcap gainer after strong Q1; Jefferies upgrades to Buy, check target...\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Moneycontrol.com\"}],\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"17 Sep, 2026\",\"party\":\"Bofa Securities Europe Sa\",\"side\":\"Buy\",\"quantity\":\"150000\",\"price\":\"2,826.6\",\"source\":\"Public market-data page\",\"value\":\"\u20b942.40 Cr\"},{\"deal_type\":\"Block\",\"date\":\"17 Sep, 2026\",\"party\":\"North Rock Sg Vcc\",\"side\":\"Sell\",\"quantity\":\"150000\",\"price\":\"2,826.6\",\"source\":\"Public market-data page\",\"value\":\"\u20b942.40 Cr\"},{\"deal_type\":\"Block\",\"date\":\"04 Sep, 2026\",\"party\":\"Kotak Mahindra Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"2793000\",\"price\":\"2,826.6\",\"source\":\"Public market-data page\",\"value\":\"\u20b9789.47 Cr\"},{\"deal_type\":\"Block\",\"date\":\"04 Sep, 2026\",\"party\":\"Fosun Pharma Industrial Pte. Ltd.\",\"side\":\"Sell\",\"quantity\":\"2793000\",\"price\":\"2,826.6\",\"source\":\"Public market-data page\",\"value\":\"\u20b9789.47 Cr\"},{\"deal_type\":\"Block\",\"date\":\"04 Sep, 2026\",\"party\":\"Fosun Pharma Industrial Pte. Ltd.\",\"side\":\"Sell\",\"quantity\":\"1357000\",\"price\":\"2,826.6\",\"source\":\"Public market-data page\",\"value\":\"\u20b9383.57 Cr\"},{\"deal_type\":\"Block\",\"date\":\"04 Sep, 2026\",\"party\":\"Axis Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"1357000\",\"price\":\"2,826.6\",\"source\":\"Public market-data page\",\"value\":\"\u20b9383.57 Cr\"},{\"deal_type\":\"Block\",\"date\":\"04 Sep, 2026\",\"party\":\"Fosun Pharma Industrial Pte. Ltd.\",\"side\":\"Sell\",\"quantity\":\"1039000\",\"price\":\"2,826.6\",\"source\":\"Public market-data page\",\"value\":\"\u20b9293.68 Cr\"},{\"deal_type\":\"Block\",\"date\":\"04 Sep, 2026\",\"party\":\"Icici Prudential Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"1039000\",\"price\":\"2,826.6\",\"source\":\"Public market-data page\",\"value\":\"\u20b9293.68 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gland Pharma share price rose 5.41% to \u20b93,302.40 today. See why GLAND is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":11480,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Gland Pharma Share Price Today: Why GLAND Is Rising 5.41% | 9 November 2026","_witty_meta_description":"Gland Pharma share price rose 5.41% to \u20b93,302.40 today. See why GLAND is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Gland Pharma share price today","_witty_reason_label":"Strong sector tailwinds and high volume participation","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[450],"class_list":["post-11481","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-gland"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=11481"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11481\/revisions"}],"predecessor-version":[{"id":11482,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11481\/revisions\/11482"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/11480"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=11481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=11481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=11481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}